Phytotherapeutic Potential of Medicinal Plants for Atopic Dermatitis: Centella asiatica, Clinacanthus nutans, Senna alata, and Coccinia grandis.

IF 4.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Biomolecules & Therapeutics Pub Date : 2026-05-01 Epub Date: 2025-04-30 DOI:10.4062/biomolther.2025.115
Thitiluck Swangsri, Naowarat Saralamba
{"title":"Phytotherapeutic Potential of Medicinal Plants for Atopic Dermatitis: <i>Centella asiatica</i>, <i>Clinacanthus nutans</i>, <i>Senna alata</i>, and <i>Coccinia grandis</i>.","authors":"Thitiluck Swangsri, Naowarat Saralamba","doi":"10.4062/biomolther.2025.115","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder with significant global health implications, particularly in low-resource settings. In many Asian countries, traditional herbal medicine remains an integral part of healthcare and presents promising alternatives for managing AD. This review examines the therapeutic potential of four ethnomedicinal plants; Centella asiatica, Clinacanthus nutans, Senna alata, and Coccinia grandis, focusing on their anti-inflammatory, antimicrobial, and antioxidant activities. Evidence from preclinical and clinical studies highlights key bioactive compounds and underlying mechanisms, demonstrating their efficacy in alleviating AD symptoms and supporting skin barrier restoration. Comparative analysis suggests complementary and potentially synergistic effects across these species, targeting multiple aspects of AD pathophysiology. However, translation into clinical practice is constrained by inconsistent formulations, limited human trials, bioavailability challenges, and regulatory variability. Future directions include the development of standardized extracts, nanotechnology-based delivery systems, integration with conventional therapies, omics-driven precision medicine, and harmonized regulatory frameworks. Collectively, these strategies outline a therapeutic development pipeline for advancing plant-based interventions for AD from traditional use to clinical application.</p>","PeriodicalId":8949,"journal":{"name":"Biomolecules & Therapeutics","volume":"34 3","pages":"530-543"},"PeriodicalIF":4.9000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13149130/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecules & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4062/biomolther.2025.115","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disorder with significant global health implications, particularly in low-resource settings. In many Asian countries, traditional herbal medicine remains an integral part of healthcare and presents promising alternatives for managing AD. This review examines the therapeutic potential of four ethnomedicinal plants; Centella asiatica, Clinacanthus nutans, Senna alata, and Coccinia grandis, focusing on their anti-inflammatory, antimicrobial, and antioxidant activities. Evidence from preclinical and clinical studies highlights key bioactive compounds and underlying mechanisms, demonstrating their efficacy in alleviating AD symptoms and supporting skin barrier restoration. Comparative analysis suggests complementary and potentially synergistic effects across these species, targeting multiple aspects of AD pathophysiology. However, translation into clinical practice is constrained by inconsistent formulations, limited human trials, bioavailability challenges, and regulatory variability. Future directions include the development of standardized extracts, nanotechnology-based delivery systems, integration with conventional therapies, omics-driven precision medicine, and harmonized regulatory frameworks. Collectively, these strategies outline a therapeutic development pipeline for advancing plant-based interventions for AD from traditional use to clinical application.

药用植物治疗特应性皮炎的潜力:积雪草、山棘草、番泻草和大球虫。
特应性皮炎(AD)是一种慢性炎症性皮肤病,具有重大的全球健康影响,特别是在低资源环境中。在许多亚洲国家,传统草药仍然是医疗保健的一个组成部分,并为管理AD提供了有希望的替代方案。本文综述了四种民族药用植物的治疗潜力;积雪草、山棘草、泻泻草和大球虫,重点研究其抗炎、抗菌和抗氧化活性。来自临床前和临床研究的证据强调了关键的生物活性化合物和潜在的机制,证明了它们在缓解AD症状和支持皮肤屏障恢复方面的功效。比较分析表明,这些物种之间存在互补和潜在的协同效应,针对阿尔茨海默病病理生理的多个方面。然而,转化为临床实践受到不一致的配方、有限的人体试验、生物利用度挑战和监管可变性的限制。未来的方向包括标准化提取物的开发、基于纳米技术的递送系统、与传统疗法的整合、组学驱动的精准医学以及协调的监管框架。总的来说,这些策略概述了将基于植物的AD干预措施从传统用途推进到临床应用的治疗开发管道。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.60
自引率
8.10%
发文量
72
审稿时长
6-12 weeks
期刊介绍: Biomolecules & Therapeutics (Biomolecules & Therapeutics) (Print ISSN 1976-9148, Online ISSN 2005-4483) is an international, peer-reviewed, open access journal that covers pharmacological and toxicological fields related to bioactive molecules and therapeutics. It was launched in 1993 as "The Journal of Applied Pharmacology (ISSN 1225-6110)", and renamed "Biomolecules & Therapeutics" (Biomol Ther: abbreviated form) in 2008 (Volume 16, No. 1). It is published bimonthly in January, March, May, July, September and November. All manuscripts should be creative, informative, and contribute to the development of new drugs. Articles in the following categories are published: review articles and research articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书